NCT05188508 - Pembrolizumab, Olaparib, and Temozolomide for People With Glioma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 14, 2022

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

Glioma

Interventions

DRUG

Pembrolizumab

Patients will receive pembrolizumab 200mg IV on day 1 (± 3days) of each cycle. Pembrolizumab will continue every 21 days (± 3 days) throughout the trial.

COMBINATION_PRODUCT

Olaparib and Temozolomide

Olaparib and temozolomide will begin on cycle 3 day 1 and continue through cycle 11. Olaparib will be dosed 200mg orally twice a day (bid) days 1-7 each cycle. Temozolomide 50 mg/m2 will be administered orally days 1-7 each cycle.

Trial Locations (10)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Suffolk -Commack (Limited Protocol Activities), Commack

18103

RECRUITING

Lehigh Valley Health Network (Data Collection Only), Allentown

33143

RECRUITING

BAPTIST ALLIANCE - MCI (Data Collection Only), Miami

06102

RECRUITING

Hartford Healthcare Alliance (Data Collection Only), Hartford

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER